- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Wall Street Analysts Believe Nuvectis Pharma (NVCT) Could Rally 62.5%: Here's is How to Trade | 1 | Zacks | ||
| 05.05. | Nuvectis Pharma, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 05.05. | Nuvectis Pharma, Inc. Reports First Quarter 2026 Financial Results and Business Highlights | 270 | GlobeNewswire (Europe) | NXP900 Phase 1b clinical program continues to enroll patients at select sites in the USNXP900 preclinical presentations at the 2026 American Association for Cancer Research ("AACR") Annual Meeting"... ► Artikel lesen | |
| 05.05. | Nuvectis Pharma, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 31.03. | Nuvectis Pharma, Inc.: Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2026 American Association for Cancer Research Meeting | 1 | GlobeNewswire (USA) | ||
| 11.02. | Nuvectis Pharma GAAP EPS of -$1.32 | 1 | Seeking Alpha | ||
| 11.02. | Nuvectis Pharma, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 11.02. | Nuvectis Pharma, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| NUVECTIS PHARMA Aktie jetzt für 0€ handeln | |||||
| 11.02. | Nuvectis Pharma, Inc. Reports 2025 Financial Results and Business Highlights | 187 | GlobeNewswire (Europe) | FORT LEE, N.J., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative... ► Artikel lesen | |
| 17.12.25 | Nuvectis startet Phase-1b-Studie zur Kombination von NXP900 mit Osimertinib bei Lungenkrebs | 2 | Investing.com Deutsch | ||
| 17.12.25 | Nuvectis Pharma, Inc.: Nuvectis Pharma Announces the Initiation of the Phase 1b Study of NXP900 in Combination with Osimertinib in Patients with NSCLC | 199 | GlobeNewswire (Europe) | Fort Lee, NJ, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT), a clinical stage biopharmaceutical company focused on the development of innovative precision medicines for the... ► Artikel lesen | |
| 03.12.25 | Nuvectis Pharma stock rating reiterated at Buy by H.C. Wainwright | 1 | Investing.com | ||
| 25.11.25 | Nuvectis Pharma, Inc.: Nuvectis Pharma to Host a Virtual Key Opinion Leader Meeting to Discuss the NXP900 Phase 1b Program in Advanced Solid Tumors, Including the Combination with Osimertinib in NSCLC | 2 | GlobeNewswire (USA) | ||
| 11.08.25 | Nuvectis Pharma, Inc.: Nuvectis Pharma Announces the Initiation of the Phase 1b Program for NXP900 | 574 | GlobeNewswire (Europe) | The Phase 1b program is designed to evaluate the clinical activity of NXP900 as a single agent in patients with advanced solid tumors whose cancers harbor specific genetic alterations, and in combination... ► Artikel lesen | |
| 05.08.25 | Nuvectis Pharma, Inc. Reports Second Quarter 2025 Financial Results and Business Highlights | 427 | GlobeNewswire (Europe) | NXP900 becomes the lead drug candidate after successfully completing the Phase 1a dose escalation study in patients with advanced solid tumors and a drug-drug interaction study in healthy volunteers... ► Artikel lesen | |
| 31.07.25 | Nuvectis Pharma, Inc.: Nuvectis Pharma Provides Final Clinical Data Update from the NXP800 Phase 1b Study in Ovarian Cancer and Reports Completion of the NXP900 Phase 1a Dose Escalation Study | 263 | GlobeNewswire (Europe) | Available data from 13 patients with recurrent, platinum resistant, ARID1a-mutated ovarian cancer treated with 75 mg/day in the NXP800 Phase 1b study includes 2 partial responses and 3 stable diseases... ► Artikel lesen |
16 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 28,350 | -1,56 % | BARCLAYS stuft QIAGEN NV auf 'Equal Weight' | LONDON (dpa-AFX Analyser) - Die britische Investmentbank Barclays hat die Einstufung für Qiagen nach endgültigen Quartalszahlen auf "Equal Weight" mit einem Kursziel von 38 US-Dollar belassen. Analyst... ► Artikel lesen | |
| EVOTEC | 4,540 | -10,63 % | Evotec-Aktie: Explodiert der Kurs jetzt Richtung 10€? | Nachdem der Kurs der Evotec-Aktie zuletzt deutlicher in Bewegung geraten ist, richtet sich der Blick nun auf die aktuellen Unternehmenszahlen und die operative Entwicklung. Der erwartungsgemäße Start... ► Artikel lesen | |
| RELAY THERAPEUTICS | 13,220 | +2,24 % | H.C. Wainwright is Bullish on Relay Therapeutics, Inc. (RLAY) | ||
| TARSUS PHARMACEUTICALS | 64,66 | +8,07 % | Tarsus reiterates 2026 net product sales guidance of $670M-$700M as XDEMVY posts $145.4M in Q1 sales | ||
| BICARA THERAPEUTICS | 20,990 | 0,00 % | Bicara Therapeutics Inc.: Bicara Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update | Study to evaluate ficerafusp alfa in combination with pembrolizumab as a loading and every-three-week maintenance regimen in 1L R/M HPV-negative HNSCC expected to initiate in Q3 2026 Long-term follow-up... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 21,690 | +4,83 % | Arcutis Q1 2026: Umsatz steigt um 65 %, doch Expansionskosten führen zu höheren Verlusten | ||
| PRAXIS PRECISION MEDICINES | 346,46 | +0,95 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial Results | FDA accepted the new drug application (NDA) for ulixacaltamide in Essential Tremor with a PDUFA target action date of January 29, 2027, and the NDA for relutrigine, with priority review, in SCN2A... ► Artikel lesen | |
| ALLOGENE THERAPEUTICS | 2,330 | +1,30 % | Allogene Therapeutics, Inc.: Allogene Therapeutics Reports First Quarter 2026 Financial Results and Business Update | ||
| TANGO THERAPEUTICS | 25,510 | +8,55 % | Stifel Remains Bullish on Tango Therapeutics (TNGX) | ||
| C4 THERAPEUTICS | 3,660 | +15,46 % | C4 Therapeutics, Inc.: C4 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights | Progressed Plans to Establish Cemsidomide as a Potentially Foundational Treatment for Multiple Myeloma; Enrollment Ongoing in Phase 2 MOMENTUM Trial and Phase 1b Trial in Combination with Elranatamab... ► Artikel lesen | |
| BIONTECH | 78,95 | -1,07 % | Aktien im Fokus - LPKF Laser: Party bald vorbei? - BioNTech, BVB, Elmos, Rheinmetall und Verbio | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
| INHIBRX BIOSCIENCES | 117,82 | +8,44 % | Inhibrx Biosciences, Inc.: Inhibrx Reports Interim Phase 2 Data for INBRX-106 in First-Line HNSCC; Initial Results Demonstrate Potential Costimulatory Benefit Over PD-1 Monotherapy | Interim analyses show INBRX-106 + pembrolizumab achieved a 44.0% confirmed Objective Response Rate (cORR): In the preliminary confirmed response-evaluable population... ► Artikel lesen | |
| BIOVENTUS | 10,400 | +2,56 % | Bioventus, Inc.: Bioventus Reports First Quarter Financial Results | Q1 reported revenue of $132.1 million increased 7%First quarter GAAP earnings of $0.04 per diluted share compared to the prior-year period loss of $0.04 per diluted shareNon-GAAP earnings* of $0.15... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 26,850 | -8,24 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update | - NDA for lorundrostat in adults with hypertension accepted by FDA; assigned PDUFA target date of December 22, 2026 - - Conference call today at 4:30 p.m. ET - RADNOR, Pa., May 06, 2026 (GLOBE NEWSWIRE)... ► Artikel lesen | |
| ERASCA | 10,450 | +0,67 % | Erasca, Inc.: Erasca Reports First Quarter 2026 Business Updates and Financial Results | Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targeted... ► Artikel lesen |
NUVECTIS PHARMA INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +1,130 (+10,37 %) liegt der Kurs bei 12,030 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NUVECTIS PHARMA INC finden Sie auf Wallstreet Online.